Allianz SE Cuts Holdings in CVS Health Corporation $CVS

Allianz SE decreased its position in CVS Health Corporation (NYSE:CVS) by 6.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 77,377 shares of the pharmacy operator’s stock after selling 5,529 shares during the period. Allianz SE’s holdings in CVS Health were worth $5,337,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Jennison Associates LLC raised its stake in shares of CVS Health by 503.8% during the first quarter. Jennison Associates LLC now owns 1,896,341 shares of the pharmacy operator’s stock worth $128,477,000 after acquiring an additional 1,582,257 shares in the last quarter. Cantor Fitzgerald Investment Advisors L.P. raised its stake in shares of CVS Health by 1.6% during the second quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 409,735 shares of the pharmacy operator’s stock valued at $28,264,000 after acquiring an additional 6,615 shares during the last quarter. Brandywine Global Investment Management LLC grew its position in shares of CVS Health by 20.1% in the 1st quarter. Brandywine Global Investment Management LLC now owns 3,421,519 shares of the pharmacy operator’s stock worth $231,808,000 after buying an additional 572,533 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its position in CVS Health by 122.5% during the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 565,152 shares of the pharmacy operator’s stock valued at $38,289,000 after purchasing an additional 311,098 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of CVS Health by 1.4% in the 1st quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 708,479 shares of the pharmacy operator’s stock worth $47,999,000 after purchasing an additional 9,634 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 0.7%

NYSE CVS opened at $80.44 on Thursday. The company has a quick ratio of 0.62, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $85.15. The firm has a market capitalization of $102.11 billion, a price-to-earnings ratio of 211.69, a PEG ratio of 0.87 and a beta of 0.60. The company has a fifty day moving average of $77.50 and a two-hundred day moving average of $69.74.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The firm had revenue of $102.87 billion during the quarter, compared to analysts’ expectations of $98.85 billion. During the same period in the previous year, the company earned $1.09 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.3%. The ex-dividend date was Thursday, October 23rd. CVS Health’s payout ratio is presently 700.00%.

Insider Transactions at CVS Health

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the transaction, the director owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.22% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CVS. Weiss Ratings reiterated a “hold (c-)” rating on shares of CVS Health in a research note on Tuesday. Evercore ISI lifted their target price on shares of CVS Health from $85.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Argus lifted their price objective on CVS Health from $80.00 to $91.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Royal Bank Of Canada lifted their price objective on CVS Health from $81.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Finally, UBS Group increased their price target on shares of CVS Health from $79.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, October 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.45.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.